Lifecore Biomedical, Inc.
LFCR
$6.38
$0.213.40%
NASDAQ
| 02/23/2025 | 11/24/2024 | 08/25/2024 | 05/26/2024 | 02/25/2024 | |
|---|---|---|---|---|---|
| Revenue | -1.54% | 8.01% | 0.75% | 21.64% | 34.55% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.54% | 8.01% | 0.75% | 21.64% | 34.55% |
| Cost of Revenue | 6.30% | 6.37% | -11.36% | -11.78% | 32.37% |
| Gross Profit | -17.23% | 11.32% | 97.47% | 122.03% | 39.14% |
| SG&A Expenses | 2.49% | 16.66% | 53.64% | -0.57% | -4.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.52% | 8.40% | 5.80% | -7.35% | 17.47% |
| Operating Income | -1,749.19% | -17.27% | -22.52% | 143.54% | 96.87% |
| Income Before Tax | -198.50% | -146.05% | -29.81% | 80.57% | 233.23% |
| Income Tax Expenses | -103.69% | 166.15% | -128.41% | -124.78% | 210.00% |
| Earnings from Continuing Operations | -199.89% | -146.14% | -28.71% | 80.85% | 230.49% |
| Earnings from Discontinued Operations | -- | -- | -- | 100.13% | 103.36% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -194.48% | -146.22% | -50.92% | 81.97% | 142.82% |
| EBIT | -1,749.19% | -17.27% | -22.52% | 143.54% | 96.87% |
| EBITDA | -111.53% | 11.14% | -35.17% | 204.01% | 350.27% |
| EPS Basic | -191.55% | -154.26% | -48.71% | 82.21% | 142.56% |
| Normalized Basic EPS | -142.00% | -137.88% | -19.72% | 51.35% | 280.31% |
| EPS Diluted | -211.08% | -165.07% | -49.84% | 82.21% | 135.12% |
| Normalized Diluted EPS | -150.43% | -145.28% | -19.72% | 51.35% | 250.20% |
| Average Basic Shares Outstanding | 21.43% | 12.81% | 1.49% | 1.96% | 0.61% |
| Average Diluted Shares Outstanding | 1.12% | -5.65% | 1.49% | 1.96% | 20.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |